2021
Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Yu J, Tsay C, Sasaki C, Son YH, Decker RH, Mehra S, Burtness B. Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. Oral Oncology 2021, 122: 105585. PMID: 34688055, DOI: 10.1016/j.oraloncology.2021.105585.Peer-Reviewed Original ResearchConceptsNon-cancer mortalitySecond primary cancerExternal beam radiationOPC patientsPrimary cancerOral cavityHigher cancer-specific mortalityOropharyngeal squamous cell cancerBrachytherapy-treated patientsElectronic medical record dataImpact of brachytherapyInstitutional tumor registryCancer-specific mortalitySquamous cell cancerProportional hazards regressionCause of deathMedical record dataBeam radiationEligible patientsMortality HROropharynx SCCPrimary malignancySmoking historyPrimary outcomeTreatment regimenExtranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival
Breen CT, Chao J, Mehra S, Kohli N. Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival. Annals Of Otology Rhinology & Laryngology 2021, 131: 412-419. PMID: 34137303, DOI: 10.1177/00034894211025171.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaExtranodal mantle cell lymphomaCumulative incidenceOverall survivalCell lymphomaEnd Results 18 registriesStage IV diseaseEarly-stage diseaseCause-specific hazards modelLate-stage diseaseProportion of casesSignificant differencesExtranodal headChemoradiation therapyCommon subsiteDisease characteristicsCommon siteAnatomic sitesPrimary headRadiation therapyCommon treatmentOral cavityHazards modelStage IIIStage I
2019
1127P Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Yu J, Tsay C, Sasaki C, Son Y, Decker R, Mehra S, Burtness B. 1127P Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. Annals Of Oncology 2019, 30: v457. DOI: 10.1093/annonc/mdz252.019.Peer-Reviewed Original ResearchNon-cancer mortalityExternal beam radiationOverall survivalCancer mortalityOral cavityOropharyngeal squamous cell cancerBrachytherapy-treated patientsGenentech/RocheImpact of brachytherapyReceipt of brachytherapySecond primary cancerEffect of comorbiditySquamous cell cancerProportional hazards regressionSingle-institution studyHigher cancer mortalityBeam radiationElectronic medical recordsGlaxo Smith KlineBristol-Myers SquibbEligible patientsOropharynx SCCHPV statusPrimary malignancySecondary outcomes
2018
Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival
Li H, Torabi SJ, Yarbrough WG, Mehra S, Osborn HA, Judson B. Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival. JAMA Otolaryngology - Head & Neck Surgery 2018, 144: 519-525. PMID: 29801040, PMCID: PMC6583856, DOI: 10.1001/jamaoto.2018.0395.Peer-Reviewed Original ResearchConceptsHPV-positive statusHuman papillomavirus (HPV) statusOverall survivalHPV statusOral cavityHPV positivityRetrospective population-based cohort studyPopulation-based cohort studyCox multivariate regression modelNeck squamous cell carcinomaHPV-negative statusImproved overall survivalNational Cancer DatabaseHPV-negative tumorsHPV-positive tumorsIndependent prognostic factorHuman papillomavirus positivityUpper aerodigestive tractSquamous cell carcinomaLarge survival differencesCategory tumorsOropharynx subsiteCohort studyPrimary malignancyImproved survival